BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27548267)

  • 1. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Mahli A; Hellerbrand C
    Dig Dis; 2016; 34 Suppl 1():32-9. PubMed ID: 27548267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis.
    Hellerbrand C
    Dig Dis; 2010; 28(6):783-91. PubMed ID: 21525763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions.
    Åberg F; Färkkilä M
    Semin Liver Dis; 2020 May; 40(2):154-162. PubMed ID: 32069503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China.
    Fan JG
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():11-7. PubMed ID: 23855290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.
    Souza MR; Diniz Mde F; Medeiros-Filho JE; Araújo MS
    Arq Gastroenterol; 2012; 49(1):89-96. PubMed ID: 22481692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
    Bosserhoff A; Hellerbrand C
    Dig Dis; 2011; 29(4):377-83. PubMed ID: 21894008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty liver disease and obesity.
    Saadeh S
    Nutr Clin Pract; 2007 Feb; 22(1):1-10. PubMed ID: 17242448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities.
    Idalsoaga F; Kulkarni AV; Mousa OY; Arrese M; Arab JP
    Front Med (Lausanne); 2020; 7():448. PubMed ID: 32974366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis.
    Di Ciaula A; Bonfrate L; Krawczyk M; Frühbeck G; Portincasa P
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota, Liver Diseases, and Alcohol.
    Cassard AM; Gérard P; Perlemuter G
    Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future therapeutic strategies in NAFLD.
    Mark N; de Alwis W; Day CP
    Curr Pharm Des; 2010 Jun; 16(17):1958-62. PubMed ID: 20370671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
    Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
    Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD.
    Boursier J; Chaigneau J; Roullier V; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Deugnier Y; Rousselet MC; Cavaro-Ménard C; Gallois Y; Aubé C; Calès P;
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):974-81. PubMed ID: 21904208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.
    Ratziu V; Ghabril M; Romero-Gomez M; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):28-38. PubMed ID: 30300289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.